Evidence map›Paper›PMID 38956114›Full record

ArticleScientific reports2024

Optimizing immunofluorescence with high-dynamic-range imaging to enhance PD-L1 expression evaluation for 3D pathology assessment from NSCLC tumor tissue.

Hsien-Neng Huang, Chun-Wei Kuo, Yu-Ling Hung, Chia-Hung Yang, Yu-Han Hsieh, Yu-Chieh Lin, Margaret Dah-Tsyr Chang, Yen-Yin Lin, Jen-Chung Ko

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hsien-Neng HuangDepartment of Pathology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
Chun-Wei KuoDepartment of Pathology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
Yu-Ling HungJelloX Biotech Inc., Hsinchu, Taiwan.
Chia-Hung YangJelloX Biotech Inc., Hsinchu, Taiwan.
Yu-Han HsiehJelloX Biotech Inc., Hsinchu, Taiwan.
Yu-Chieh LinJelloX Biotech Inc., Hsinchu, Taiwan.
Margaret Dah-Tsyr ChangJelloX Biotech Inc., Hsinchu, Taiwan.
Yen-Yin LinJelloX Biotech Inc., Hsinchu, Taiwan.
Jen-Chung KoDepartment of Internal Medicine, National Taiwan University HospitalHsin-Chu Branch, No. 25, Ln. 442, Sec. 1, Jingguo Rd., North Dist., Hsinchu City, 300, Taiwan, ROC. e1205470@ms22.hinet.net.

Funding

Ministry of Science and Technology, Taiwan B11102
6 · The paper itself

Abstract

Assessing programmed death ligand 1 (PD-L1) expression through immunohistochemistry (IHC) is the golden standard in predicting immunotherapy response of non-small cell lung cancer (NSCLC). However, observation of heterogeneous PD-L1 distribution in tumor space is a challenge using IHC only. Meanwhile, immunofluorescence (IF) could support both planar and three-dimensional (3D) histological analyses by combining tissue optical clearing with confocal microscopy. We optimized clinical tissue preparation for the IF assay focusing on staining, imaging, and post-processing to achieve quality identical to traditional IHC assay. To overcome limited dynamic range of the fluorescence microscope's detection system, we incorporated a high dynamic range (HDR) algorithm to restore the post imaging IF expression pattern and further 3D IF images. Following HDR processing, a noticeable improvement in the accuracy of diagnosis (85.7%) was achieved using IF images by pathologists. Moreover, 3D IF images revealed a 25% change in tumor proportion score for PD-L1 expression at various depths within tumors. We have established an optimal and reproducible process for PD-L1 IF images in NSCLC, yielding high quality data comparable to traditional IHC assays. The ability to discern accurate spatial PD-L1 distribution through 3D pathology analysis could provide more precise evaluation and prediction for immunotherapy targeting advanced NSCLC.

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungFluorescent Antibody TechniqueImaging, Three-DimensionalLung NeoplasmsBiomarkers, TumorHumansImmunohistochemistryMicroscopy, ConfocalB7-H1 AntigenBiomarkers, TumorCD274 protein, humanHigh dynamic rangeImmunofluorescenceNon-small cell lung cancerProgrammed death ligand 1Three-dimensional pathology

Identifiers

PMID38956114
PMCPMC11219731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.